Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments

PURPOSE OF REVIEW: The chimeric antigen receptor (CAR) T-cell therapy is currently changing the landscape of hematologic malignancies with multiple FDA-approved cell therapy products in the USA. The current administration process of the CAR T-cell therapy is complicated, labor-intensive, and expensi...

Descripción completa

Detalles Bibliográficos
Autores principales: Geethakumari, Praveen Ramakrishnan, Ramasamy, Dheepthi Perumal, Dholaria, Bhagirathbhai, Berdeja, Jesús, Kansagra, Ankit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Health Economics (N Khera, Section Editor)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179081/
https://www.ncbi.nlm.nih.gov/pubmed/34089485
http://dx.doi.org/10.1007/s11899-021-00635-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179081/
https://www.ncbi.nlm.nih.gov/pubmed/34089485
http://dx.doi.org/10.1007/s11899-021-00635-3

Ejemplares similares